跳到正文
PR Newswire Health·· 2 小时前AI 评分18

LifeLogics 任命 Ankit Mathur 为 CEO,引领器官捐献与移植技术创新

LifeLogics Names New CEO to Lead Innovation in Organ Donation & Transplantation Technology

AI 导读

LifeLogics 任命前 UNOS 首席技术官 Ankit Mathur 为 CEO,负责推进其器官捐献与移植技术平台的现代化。Mathur 将重点加强与器官获取组织(OPO)的合作、改善客户体验并扩大捐献生态系统的互操作性。LifeLogics 成立于 2006 年,旗下产品包括供体管理平台 TrueNorth 和连接医院电子病历与 OPO 的互操作性平台 Copernicus。

正文 · 原文

Technology leader and healthcare entrepreneur to guide LifeLogics into its next chapter with a focus on innovation, customer experience, and advancing technology across organ donation and transplantation.

, /PRNewswire/ -- LifeLogics, a nonprofit technology company serving the organ and tissue donation and transplantation community, today announced the appointment of Ankit Mathur as Chief Executive Officer.

Ankit Mathur, CEO of LifeLogics, Inc.

Ankit Mathur, CEO of LifeLogics, Inc.

Mathur brings more than two decades of experience in technology, healthcare, and organizational leadership to LifeLogics, most recently serving as Chief Technology Officer of United Network for Organ Sharing (UNOS). His appointment comes as LifeLogics looks to strengthen its technology platforms, deepen customer partnerships, and help advance the organ donation and transplantation ecosystem.

"Ankit brings a rare combination of healthcare technology experience, entrepreneurial leadership, and a deep understanding of the organ donation and transplantation community," said Mathew Moss, Chair of the LifeLogics Board of Directors. "As LifeLogics enters its third decade, we see a tremendous opportunity to build on the organization's foundation while strengthening our commitment to innovation, customer partnerships, and operational excellence. We're confident Ankit is the right leader to help us realize this vision."

As CEO, Mathur will lead LifeLogics through its next phase of growth and modernization, with a focus on strengthening the company's partnerships with organ procurement organizations (OPOs), advancing its technology platforms, improving the customer experience, and expanding interoperability across the donation ecosystem.

"Behind every organ donation is a family navigating one of the most difficult moments of their lives. The work our customers do every day to honor those gifts and help save lives is extraordinary, and LifeLogics has an important responsibility to support them," said Mathur.

"That responsibility goes beyond building great technology. It means being a trusted partner, providing the service and support our customers deserve, and making their work easier so they can focus on what matters most. I'm excited to work alongside our customers and the LifeLogics team to build on the company's foundation while raising the bar for what our customers should expect from their technology partner."

At UNOS, Mathur helped guide technology strategy and modernization initiatives supporting the nation's organ donation and transplantation system. Previously, he was Chief Delivery Officer for the U.S. Digital Service at the White House. Earlier in his career, Mathur founded Roundtrip, a healthcare technology company ensuring patients have reliable access to transportation. Mathur is a three-time graduate of Virginia Commonwealth University and serves on the boards of the Richmond Technology Council (rvatech/) and VCU's School of Business Foundation.

ABOUT LIFELOGICS

Founded in 2006 with the support of a consortium of organ procurement organizations, LifeLogics is a nonprofit technology company providing software and technology services to the organ and tissue donation community. Its solutions include TrueNorth, a donor management platform for organ procurement organizations; Copernicus, an interoperability platform connecting hospital electronic medical record systems with OPOs; and donor registry technology supporting state and national donation programs.

For more information, visit www.lifelogics.org.

Media Contact: Tim Bourgeois at [email protected] or 508-561-9763.

SOURCE LifeLogics, Inc.

来源:PR Newswire Health · prnewswire.com

AI 摘要声明:站内标题、摘要与推荐理由由模型基于公开来源生成,属机器生成内容,非原文;本页内容仅供医药行业信息参考,不构成医疗建议、诊断或用药依据。